Squamous cell carcinoma of the skin future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2], Raviteja Guddeti, M.B.B.S. [3]
Future or Investigational Therapies
Future or Investigational Therapies
In 2007, Australian biopharmaceutical company Clinuvel Pharmaceuticals Limited began clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)[1] to provide photoprotection for organ transplant patients against squamous cell carcinoma of the skin and actinic keratosis.[2][3]
Cetuximab a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin, as initially suggested by case reports.
Use of natural agents in cancer therapy is increasing. For oral squamous cell carcinoma , use of curcumin microemulsions is under considerations. New modalities like use of ultra sound mediated delivery of these microemulsions. [4]
References
References
- ↑ “World Health Organisation assigns CUV1647 generic name” (PDF). Clinuvel. 2008. Retrieved 2008-06-17.
- ↑ Clinuvel » Investors » FAQs
- ↑ PharmaAsia – Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials
- ↑ Lenaz G, Fato R, Baracca A, Solaini G, Parenti Castelli G, Rabbi A (1988). “Dynamics of biological membranes”. Ann. Ist. Super. Sanita. 24 (1): 9–21. PMID 3289448.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH